Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer-MedSci.cn

Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer

Guan, X; Li, HC; Chen, QJ; Hua, B; Li, JJ; Ma, F; Wang, YS; Xu, H; Liu, C; Yang, Q; Ma, AX